• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

bySze Wah Samuel ChanandHarsh Shah
February 10, 2021
in Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this phase 1-2 clinical trial, an adenovirus viral vector expressing non-structural hepatitis C proteins was safe in a high-risk population.

2. The vaccine did not have a significant impact on chronic hepatitis C infection prevention.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The hepatitis C virus (HCV) is one of the most prevalent blood-borne infections while conferring significant mortality and morbidity. A vaccine strategy is important in reducing the spread among high-risk populations and may be essential in the goal of eliminating the disease. In this randomized trial, participants were either assigned to a recombinant chimpanzee adenovirus 3 vector or placebo group. At six months, there was no significant difference in the rates of chronic HCV infection between vaccine and placebo groups. T-cell responses were detected in the vaccine group and a minimal amount was seen in the placebo group. The percentages of participants with serious adverse events were similar between both groups. The most common serious adverse event was related to increased alanine transaminase (ALT) levels. The limitation of the study was the inability to reveal some level of efficacy in the prevention of HCV infections even though the strategy was shown to be safe. Overall, this trial demonstrates that this vaccine strategy has no evidence of efficacy and highlights the difficulty in formulating an HCV vaccine given chronic infection involves likely immune-escape mechanisms.

Click here to read the study in the NEJM

Relevant Reading: Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection

In-Depth [randomized controlled trial]: In this phase 1-2, double-blinded, placebo-controlled randomized trial of 548 participants, participants at risk of HCV infection were enrolled based on a history of recent intravenous drug use were assigned 1:1 to receive vaccine or placebo in a day 0 and day 56 regiment. The vaccine was a recombinant chimpanzee adenovirus 3 vector followed by a recombinant modified vaccinia Ankara boost encoding non-structural proteins of the HCV. The primary endpoint was the rate of chronic HCV infection at 6 months defined by HCV RNA levels. The rate of chronic HCV infection was similar between both groups (hazard ratio [HR] 1.53, 95% confidence interval (CI) of 0.66 to 3.55). The geometric mean peak HCV RNA level was 152 x 103 international units (IU) per milliliter (mL) in the vaccine group compared to 1804 x 103 IU per mL in the placebo group. Immunogenicity was assessed before viral infection. T-cell responses were detected in 78% of the vaccine group and only in 3% of the placebo group. The rate of serious adverse events was similar between both groups, with most events related to a laboratory detected adverse event. The most frequent laboratory detected adverse event was an elevation in the ALT levels which was detected in 50% of the vaccine group and 39% in the placebo group. Overall, the trial determined the adenovirus vaccine strategy was safe; however the effectiveness to prevent subsequent HCV infection was not able to be determined.

RELATED REPORTS

Regular physical activity may improve vaccine effectiveness against COVID-19 outcomes

Wellness Check: Exercise

COVID-19 vaccine associated with temporary decreased rates of successful in-vitro fertilization following vaccination

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adenovirus vectoreffectivenesshepatitis Cvaccinevaccine safety
Previous Post

Tirbanibulin ointment potentially effective for actinic keratosis treatment

Next Post

Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma

RelatedReports

Reduced gestational weight gain with lifestyle intervention
Chronic Disease

Regular physical activity may improve vaccine effectiveness against COVID-19 outcomes

November 28, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Wellness

Wellness Check: Exercise

November 24, 2022
Infectious Disease

COVID-19 vaccine associated with temporary decreased rates of successful in-vitro fertilization following vaccination

November 9, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: World Mental Health Day, Beneath the Band-aid, Trouble in Uganda and Carbon Monoxide Leak Sickens Dozens!

October 18, 2022
Next Post
Quick Take: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial

Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Reduced risk of SARS-CoV-2 with presence of antibodies

#VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression

#VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Evaluation of medical school parental leave policies in the United States
  • Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer
  • Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options